Nama's AI scorecard currently rates Precigen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PGEN's P/E ratio?

Precigen trades at a trailing price-to-earnings ratio of 44.7.

When does PGEN report earnings?

Precigen's next scheduled report is on Mar 24, 2027. Analysts expect EPS of $0.10.

What is the PGEN price target?

The median analyst price target from 3 analysts is $12.00, with a range of $11.00 – $17.95.

Is PGEN Shariah compliant?

Nama's AAOIFI-style screen reads Precigen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Precigen (PGEN)

Healthcare · Biotechnology · NASDAQ

Precigen (PGEN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.60B, a trailing price-to-earnings ratio of 44.7 and a free-cash-flow yield of -6.5%. Over the most recent reported fiscal year, revenue grew 146.7%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +92.4% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-50.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.60B
Trailing P/E	44.7
Price / book	37.2
Price / sales	18.6
FCF yield	-6.5%
Dividend yield	—
Gross margin	90.7%
Operating margin	-46.1%
Net margin	-184.0%
Revenue growth (YoY)	+146.7%
Revenue growth (3-yr annual)	-28.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

PGEN earnings

Next report: Mar 24, 2027 (Q4 2026, EPS estimate $0.10). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.08	$0.08	+0.0%	$74.15M
Q2 2026	Aug 4, 2026	$0.05	-$0.01	+600.0%	$54.98M
Q1 2026	May 13, 2026	-$0.02	-$0.04	+50.0%	$23.25M
Q4 2025	Mar 25, 2026	-$0.01	-$0.08	+87.5%	$4.57M

PGEN analyst price target

Median target $12.00 from 3 analysts, ranging $11.00 – $17.95.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live PGEN data on Nama Insights →

PGEN FAQ

Is PGEN a buy?: Nama's AI scorecard currently rates Precigen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PGEN's P/E ratio?: Precigen trades at a trailing price-to-earnings ratio of 44.7.
When does PGEN report earnings?: Precigen's next scheduled report is on Mar 24, 2027. Analysts expect EPS of $0.10.
What is the PGEN price target?: The median analyst price target from 3 analysts is $12.00, with a range of $11.00 – $17.95.
Is PGEN Shariah compliant?: Nama's AAOIFI-style screen reads Precigen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.